肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2019 多学科共识声明：Ⅲ期非小细胞肺癌患者的临床管理

2019-06-06 国外肿瘤科相关专家小组（统称） Clin Transl Oncol. 2019 Jun 6.

Ⅲ期非小细胞肺癌临床管理

Ⅲ期非小细胞肺癌(NSCLC)是一种异质性疾病，本文主要内容涉及Ⅲ期非小细胞肺癌患者的临床管理中，涉及分期，诱导后恢复的方法，治疗前功能评估，系统治疗，放射治疗，手术治疗以及随访等内容。

中文标题：

2019 多学科共识声明：Ⅲ期非小细胞肺癌患者的临床管理

英文标题：

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2019-06-06

简要介绍：

Ⅲ期非小细胞肺癌(NSCLC)是一种异质性疾病，本文主要内容涉及Ⅲ期非小细胞肺癌患者的临床管理中，涉及分期，诱导后恢复的方法，治疗前功能评估，系统治疗，放射治疗，手术治疗以及随访等内容。 

拓展指南：与非小细胞肺癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 多学科共识声明：Ⅲ期非小细胞肺癌患者的临床管理)] GetToolGuiderByIdResponse(projectId=1, id=3efda1c001ea77a3, title=2019 多学科共识声明：Ⅲ期非小细胞肺癌患者的临床管理, enTitle=Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer., guiderFrom=Clin Transl Oncol. 2019 Jun 6., authorId=null, author=, summary=Ⅲ期非小细胞肺癌(NSCLC)是一种异质性疾病，本文主要内容涉及Ⅲ期非小细胞肺癌患者的临床管理中，涉及分期，诱导后恢复的方法，治疗前功能评估，系统治疗，放射治疗，手术治疗以及随访等内容。 , cover=, journalId=null, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Jun 06 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>Ⅲ期非小细胞肺癌(NSCLC)是一种异质性疾病，本文主要内容涉及Ⅲ期非小细胞肺癌患者的临床管理中，涉及分期，诱导后恢复的方法，治疗前功能评估，系统治疗，放射治疗，手术治疗以及随访等内容。 </div> <div><br> </div> 拓展指南：<strong>与<font color=red>非小细胞肺癌</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=f6e3a1c001ea7421" title="NCCN临床实践指南：非小细胞肺癌（2019.V5）" target=_blank>NCCN临床实践指南：非小细胞肺癌（2019.V5）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=152491c001e17850" title="2019 加拿大共识：渐进性，假进行性和寡转移性非小细胞肺癌" target=_blank>2019 加拿大共识：渐进性，假进行性和寡转移性非小细胞肺癌</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=4a7651c0016990a7" title="驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）" target=_blank>驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ed4131c00169666e" title="美国国家综合癌症网络非小细胞肺癌指南2019 V1 版更新要点解读" target=_blank>美国国家综合癌症网络非小细胞肺癌指南2019 V1 版更新要点解读</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=3e56c1c00169a8fd" title="NCCN临床实践指南：非小细胞肺癌（2019.V3）" target=_blank>NCCN临床实践指南：非小细胞肺癌（2019.V3）</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E9%9D%9E%E5%B0%8F%E7%BB%86%E8%83%9E%E8%82%BA%E7%99%8C" target=_blank>有关非小细胞肺癌更多指南</a></ul>, tagList=[TagDto(tagId=55530, tagName=Ⅲ期非小细胞肺癌), TagDto(tagId=19173, tagName=临床管理)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4703, appHits=316, showAppHits=4, pcHits=3263, showPcHits=1597, likes=91, shares=9, comments=3, approvalStatus=1, publishedTime=Thu Jun 13 23:10:01 CST 2019, publishedTimeString=2019-06-06, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Jun 13 23:10:01 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 10:04:09 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 多学科共识声明：Ⅲ期非小细胞肺癌患者的临床管理)])
2019 多学科共识声明：Ⅲ期非小细胞肺癌患者的临床管理
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=965740, encodeId=fef5965e40bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b45502030, createdName=HFH168, createdTime=Sat May 15 00:59:38 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370562, encodeId=c0313e0562ff, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jul 31 14:55:55 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367766, encodeId=6f6c36e76626, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sat Jun 15 06:58:01 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2021-05-15 HFH168

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=965740, encodeId=fef5965e40bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b45502030, createdName=HFH168, createdTime=Sat May 15 00:59:38 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370562, encodeId=c0313e0562ff, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jul 31 14:55:55 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367766, encodeId=6f6c36e76626, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sat Jun 15 06:58:01 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-07-31 145fad5em27暂无昵称

    赞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=965740, encodeId=fef5965e40bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b45502030, createdName=HFH168, createdTime=Sat May 15 00:59:38 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370562, encodeId=c0313e0562ff, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jul 31 14:55:55 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367766, encodeId=6f6c36e76626, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sat Jun 15 06:58:01 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-06-15 thm112988

    好

    0